The 23andMe investor presentation, used for its 2021 SPAC merger with VG Acquisition Corp, serves as a masterclass in narrative transition. While the brand is synonymous with consumer ancestry kits, the deck repositioned the company as a data-driven biotech firm. It highlights a 'Consumer Powered Healthcare Flywheel' where 80% of customers opt-in to research, creating a massive phenotypic and genetic database. This data allows 23andMe to identify drug targets with a 2x higher probability of success compared to industry standards. The deck successfully argues that their $3.5 billion valuation…
Key takeaways
- The company leverages a database of 10.7 million genotyped customers to drive drug discovery (Slide 11).
- 80% of customers consent to research, contributing to over 4 billion phenotypic data points (Slide 15).
- 23andMe claims its genetic evidence can double the probability of success for drug approval (Slide 22).
- A strategic collaboration with GSK includes a $300 million equity investment and 50/50 cost/profit sharing (Slide 26).
- The lead therapeutic program, CD96, was identified using ML and AI applied to proprietary genetic signatures (Slide 28).
- The company is shifting toward a subscription model, 23andMe+, to provide ongoing health reports and risk scores (Slide 17).
- The transaction overview specifies an implied post-money enterprise value of $3.5 billion (Slide 36).
- Financials show a net loss of $251 million for FY20A, with an adjusted EBITDA of negative $147 million (Slide 39).
The Strategic Pivot: From Ancestry to Antibodies
The 23andMe investor presentation is a sophisticated document designed to move the investor's perception of the company from a 'one-time kit sale' business to a 'recurring data and therapeutics' powerhouse. At 47 slides (24 analyzed here), it provides a comprehensive look at how a consumer brand can leverage its user base to enter the highly regulated and high-stakes world of drug development.
The Executive Team and Vision
Slide 1 & 2: The presentation opens with a clean, branded title slide followed immediately by the key leadership. The inclusion of Evan Lovell (Virgin Group) alongside Anne Wojcicki (CEO), Steve Schoch (CFO), and Kenneth Hillan (Head of Therapeutics) signals the merger's significance. The visual theme of chromosomes at the bottom of the slides reinforces the core scientific identity of the brand.
Slide 4: This slide sets the 'Problem' stage. It characterizes the U.S. healthcare system as 'dysfunctional,' citing that 25% of spending is waste and the probability of drug success is less than 12%. By framing the industry's failure in terms of cost ($2.6B to develop a drug) and time (10 years), 23andMe prepares the audience for its 'Solution': a more efficient, data-driven approach.
Pioneering D2C Healthcare
Slide 6: 23andMe stakes its claim as the pioneer of digital D2C healthcare. It highlights its history of FDA authorizations, starting with Carrier Status in 2015 and moving through BRCA (2017) to Pharmacogenetics in 2020. This timeline is crucial for establishing regulatory credibility, an area where the company famously struggled in its early years.
Slide 8: The 'World Class Leadership' slide is a 'who's who' of tech and biotech. It lists experience from Facebook, Netflix, Amgen, Genentech, and Google. This mix of consumer tech and deep-science expertise is presented as a competitive advantage that traditional pharma companies lack.
The Data Flywheel
Slide 9 & 11: The presentation defines the core of the business as a 'big data problem.' Slide 11 introduces the 'Consumer Powered Healthcare Flywheel.' This is the most important conceptual slide in the deck. It shows how 10.7 million genotyped customers and 30k+ daily surveys feed into a research loop of phenotypic and genetic data. This loop produces insights that lead to both 'Drug Discoveries' and 'Novel Consumer Products,' which then return value to the customer, encouraging more data sharing.
Slide 13: To humanize the data, the deck uses a case study of 'Ann M.,' a customer who discovered a BRCA1 mutation through 23andMe despite not meeting traditional clinical guidelines for testing. This slide argues that 23andMe catches risks that the traditional healthcare system misses, specifically noting that 80% of people with the mutation are 'missed by the healthcare system.'
Engagement and Subscription
Slide 15: This slide focuses on the 'Meaningful, Engaging (and Fun) Experience.' It boasts that 80% of customers consent to research and that 60% of even their oldest customers (pre-2015) logged in during 2020. This high engagement is the 'moat' that allows for longitudinal data collection.
Slide 17: Here, the company introduces 23andMe+, its subscription service. This represents a shift toward recurring revenue. The service offers pharmacogenetics, heart health reports, and polygenic risk scores. By moving into 'Proactive' health management (Slide 19), 23andMe positions itself as a lifelong health partner rather than a one-off ancestry report.
Therapeutics: The Value Driver
Slide 21 & 22: Section 3 shifts entirely to therapeutics. Slide 22 presents a direct comparison between the 'Pharmaceutical Industry' and '23andMe.' It claims 23andMe can reach the IND (Investigational New Drug) stage in ~4 years compared to the industry average of 7 years, while doubling the probability of success. This is a bold claim backed by a 2015 Nature publication on the support of human genetic evidence.
Slide 24: This slide shows the power of scale. A graph demonstrates that the number of independent genetic 'hits' (potential drug targets) increases linearly as the database grows. This justifies the constant push for more consumer kit sales; every new customer makes the drug discovery engine more powerful.
Slide 26: The GSK collaboration is detailed here. With a $300M investment and 30+ joint programs, GSK provides the clinical and commercial infrastructure that 23andMe lacks. This partnership validates 23andMe's data in the eyes of institutional investors.
Slide 28: The deck highlights its lead program, CD96, an immuno-oncology target. It shows how ML and AI were used to identify a genetic signature that mirrors successful I/O drugs like Keytruda. This is the 'proof of concept' for their entire therapeutic strategy.
Financials and Projections
Slide 30 & 31: The company shows rapid scaling in validated targets, projecting a move from 2 targets in FY19A to 37 in FY24E. Slide 31 shows cumulative genotyped customers reaching 11.2 million by FY21E, while also noting that Customer Acquisition Cost (CAC) is a significant part of the investment.
Slide 33: Future growth drivers are split between 'Consumer Opportunity' (kits and subscribers) and 'Therapeutics' (validated targets). The projection of 2.9 million subscribers by FY24E is a key metric for valuation, as subscription revenue typically carries higher multiples than hardware/kit sales.
Slide 35: The TAM (Total Addressable Market) slide is massive, citing $250B for Telehealth, $825B for Prescription Drugs, and $190B for Pharma R&D. By connecting their 10M+ customers to these markets, 23andMe justifies a multi-billion dollar valuation.
Slide 36 & 39: The transaction overview confirms the $3.5 billion enterprise value. However, the 'Adjusted EBITDA Reconciliation' on Slide 39 shows the cost of this growth: a net loss of $251 million in FY20A. The company is clearly in a 'burn for growth' phase, reinvesting heavily in R&D and customer acquisition.
What 23andMe Does Well
Narrative Bridge: The deck successfully bridges the gap between a consumer 'fun' product and a 'serious' biotech company. It uses the consumer data as the 'unfair advantage' for the biotech side. · Regulatory Proof: By listing specific FDA authorizations, they neutralize the historical concern that their tests aren't 'real' medicine. · Scale as a Moat: They effectively argue that their database is a proprietary asset that cannot be easily replicated, even by big pharma. · Strategic Partnerships: The GSK slide is a massive credibility booster. It shows that one of the world's largest pharma companies is willing to bet $300M on their data.
What is Missing from the Deck
Unit Economics: While they mention CAC on Slide 31, they do not provide a clear breakdown of the Lifetime Value (LTV) of a customer or the gross margins on the kits themselves. · Competition: There is no mention of competitors like Ancestry.com or newer, more clinical-focused genetic testing companies. The deck acts as if 23andMe exists in a vacuum. · Privacy and Security: Given the sensitivity of genetic data, the lack of a dedicated slide on data security and privacy (beyond a brief mention of 'consent') is a notable omission for a public-facing document. · Path to Profitability: The EBITDA slide shows deepening losses, but there is no clear 'break-even' projection provided in the analyzed slides.
What Other Founders Can Copy
The Flywheel Graphic: Slide 11 is a perfect example of how to show multiple business units supporting each other. If your startup has a B2C and a B2B side, show how they feed each other. · Humanizing Data: Using 'Ann M.' (Slide 13) to explain a complex genetic concept makes the technology relatable and demonstrates real-world impact. · Comparative Benchmarking: Slide 22, which compares 23andMe's metrics against the 'Pharmaceutical Industry,' is a great way to show disruption. Founders should always find an industry standard to beat. · Visual Consistency: The use of the chromosome motif and a consistent color palette makes the 47-slide deck feel cohesive and professional.
Frequently asked questions
- What is 23andMe's primary business model according to the deck?
- The deck describes a 'Consumer Powered Healthcare Flywheel.' While it started with D2C DNA kits, the model now integrates a subscription service (23andMe+) and a therapeutics division. The consumer side provides the data (genotypic and phenotypic) that fuels the research side, which in turn generates drug discoveries and novel consumer products, creating a self-reinforcing loop of value and data collection.
- How does 23andMe justify its move into therapeutics?
- The company argues that traditional drug development is inefficient, with a <12% probability of success and a $2.6 billion cost per drug. 23andMe claims that by using its massive genetic database, it can reduce the time-to-IND from 7 years to approximately 4 years and double the probability of clinical success by using human genetic evidence to validate targets early.
- What are the key metrics for their consumer segment?
- Key consumer metrics include 10.7 million genotyped customers, 30,000+ daily surveys completed, and a 60% login rate for pre-2015 customers during 2020. The company also highlights the growth of its subscription service, projecting an increase from 0.1 million subscribers in FY21E to 2.9 million by FY24E.
- What is the nature of the GSK partnership?
- The partnership with GSK is a cornerstone of their therapeutics strategy. It involved a $300 million equity investment from GSK and a 50/50 split on costs and profits for joint programs. As of the deck's publication, they had over 30 joint profit-sharing programs across oncology, immunology, cardiovascular, metabolic disease, and neurology.
- What are the financial terms of the SPAC merger?
- The merger with VG Acquisition Corp (Virgin) implied a post-money enterprise value of $3.5 billion. The deal was funded by $509 million of cash in trust and $250 million in PIPE financing. Notably, both Sir Richard Branson and CEO Anne Wojcicki committed to investing $25 million each as part of the transaction.
